Lupus Pipeline Could See Momentum Following Two New US Approvals

Lupus Therapeutics Sees Improved Outlook For Challenging Area Of Drug Development

Albert Roy, executive director of the clinical research arm of the Lupus Research Alliance, talked to Scrip about the outlook for lupus drug development.

Purple ribbon
Lupus Therapeutics hopes to see advances in drug development for SLE And LN • Source: Shutterstock

Two recent US Food and Drug Administration approvals of lupus nephritis treatments are a positive signal for future drug development in this notoriously challenging disease, Lupus Therapeutics executive director Albert Roy said in a recent interview with Scrip.

Roy has a broad perspective of the field of research. Lupus Therapeutics is an affiliate of the non-profit Lupus Research...

More from Immunological

More from Therapy Areas